Angivent MR 35

Indications

Angivent MR is indicated for adult patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.

Pharmacology

Trimetazidine Dihydrochloride, a metabolic anti-ischemic agent, inhibits the 3-keto acyl CoA thiolase enzyme, redirecting energy production from fatty acids to glucose. This process enhances myocardial efficiency, reduces lactic acid production, and alleviates angina symptoms in coronary patients.

Dosage & Administration

The recommended dose is 35 mg twice daily or 20 mg thrice daily during meals. Treatment efficacy should be evaluated after three months; discontinue if no response is observed.

Interactions

No interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents, or digitalis preparations.

Contraindications

Trimetazidine is contraindicated in patients with hypersensitivity to the active substance, Parkinson’s disease, parkinsonian symptoms, severe renal impairment, or related movement disorders.

Side Effects

Common side effects include dizziness, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria, and asthenia.

Pregnancy & Lactation

Use during pregnancy and lactation is not recommended due to insufficient data on human use and potential risks to newborns/infants.

Precautions & Warnings

Angivent MR is not indicated for acute angina attacks, unstable angina pectoris, or myocardial infarction.

Therapeutic Class

Other Anti-anginal & Anti-ischemic drugs.

Storage Conditions

Store in a dry place away from light and heat, and keep out of reach of children.